COVID19 ICD10PCS Value Set for Administration of Sarilumab

{
  "compose" : {
    "exclude" : [ ],
    "include" : [ {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "extension" : [ {
        "extension" : [ {
          "valueString" : "concept",
          "url" : "path"
        }, {
          "url" : "count",
          "valueInteger" : 2
        } ],
        "url" : "http://health-samurai.io/extensions/excised-data"
      } ]
    } ]
  },
  "date" : "2023-06-21T18:16:37-04:00",
  "meta" : {
    "versionId" : "5",
    "lastUpdated" : "2023-12-21T17:43:03.000-05:00",
    "profile" : [ "http://hl7.org/fhir/StructureDefinition/shareablevalueset", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/computable-valueset-cqfm", "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm" ]
  },
  "publisher" : "Clinical Architecture",
  "jurisdiction" : [ {
    "coding" : [ {
      "system" : "urn:iso:std:iso:3166",
      "code" : "US"
    } ]
  } ],
  "purpose" : "(Clinical Focus: This set of values contains terms related to administration of sarilumab.),(Data Element Scope: ),(Inclusion Criteria: Includes introduction of sarilumab into central or peripheral veins via open or percutaneous routes.),(Exclusion Criteria: Excludes administration of other interleukin-6 antagonists (e.g., tocilizumab) and routes of administration that do not involve open or percutaneous procedures (i.e. oral administration).)",
  "name" : "COVID19ICD10PCSValueSetForAdministrationOfSarilumab",
  "experimental" : false,
  "resourceType" : "ValueSet",
  "expansion" : {
    "contains" : [ {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "XW033G5",
      "display" : "Introduction of Sarilumab into Peripheral Vein, Percutaneous Approach, New Technology Group 5",
      "version" : "2024"
    }, {
      "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
      "code" : "XW043G5",
      "display" : "Introduction of Sarilumab into Central Vein, Percutaneous Approach, New Technology Group 5",
      "version" : "2024"
    } ],
    "total" : 2,
    "identifier" : "urn:uuid:bc18a98a-3179-43a1-8c58-c78d556df129",
    "timestamp" : "2024-06-14T16:16:46-04:00"
  },
  "title" : "COVID19 ICD10PCS Value Set for Administration of Sarilumab",
  "extension" : [ {
    "valueString" : "Clinical Architecture",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author"
  }, {
    "valueDate" : "2023-06-21",
    "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate"
  }, {
    "valueDate" : "2020-12-17",
    "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate"
  }, {
    "url" : "http://health-samurai.io/extensions/source",
    "valueCode" : "db"
  } ],
  "status" : "retired",
  "id" : "2.16.840.1.113883.3.3616.200.110.102.4017",
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.3616.200.110.102.4017",
  "identifier" : [ {
    "system" : "urn:ietf:rfc:3986",
    "value" : "urn:oid:2.16.840.1.113883.3.3616.200.110.102.4017"
  } ],
  "version" : "20201217"
}